Hinge Health, Inc.
HNGE
$75.14
+6.49%
Hinge Health, Inc. is a digital healthcare technology company that operates a platform for treating and preventing chronic musculoskeletal (MSK) conditions through AI-powered motion tracking and personalized care plans. The company is a recognized leader and disruptor in the digital MSK therapy space, leveraging its proprietary dataset of patient movement to build a sustainable competitive moat. The current investor narrative is intensely focused on its high-growth trajectory, with recent headlines highlighting its 51% revenue growth and expanding profitability, positioning it as a compelling long-term opportunity in the rapidly digitizing healthcare market.…
HNGE
Hinge Health, Inc.
$75.14
Related headlines
Investment Opinion: Should I buy HNGE Today?
Rating: Hold. The core thesis is that HNGE is a compelling, high-growth disruptor with a proven business model, but its extreme valuation and lack of current profitability create an asymmetric risk/reward profile that favors waiting for a better entry point or clearer signs of sustainable margin improvement. Supporting evidence for this cautious stance includes the stock's rich valuation (PS 6.26x, EV/Sales 7.95x), its deeply negative profitability metrics (net margin -89.86%), and its extended technical position trading at 98% of its 52-week high. While the 51% revenue growth and 79.83% gross margin are exceptionally strong, the forward P/E of 20.76x—which implies significant future earnings—already prices in a successful transition to profitability. The stock's 74.73% one-year run-up suggests much of the near-term optimism is already reflected in the price. The thesis would upgrade to a Buy if the stock experiences a meaningful pullback (e.g., towards the $50-$55 range) that improves the risk/reward, or if the company demonstrates consecutive quarters of substantial operating margin expansion towards breakeven. It would downgrade to a Sell if revenue growth decelerates sharply (e.g., below 30% YoY) or if net losses widen unexpectedly, calling the path to profitability into question. Based on the current data, the stock is overvalued relative to its present financials but may be fairly valued if one has high conviction in its long-term growth and margin trajectory.
Sign up to view all
HNGE 12-Month Price Forecast
HNGE is a high-potential, high-risk story at a crossroads. The company's fundamentals—explosive growth and superb gross margins—are impressive and justify investor interest. However, the investment is a bet on future profitability that is already richly priced, with the stock trading near its 52-week high after a massive run. The neutral stance reflects the view that the current price fairly balances this exceptional growth against the significant execution risk and valuation sensitivity. The stance would upgrade to bullish on evidence of sustained operating margin improvement or a pullback to a more attractive entry point. It would turn bearish on any material growth deceleration or failure to progress toward profitability.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on Hinge Health, Inc.'s 12-month outlook, with a consensus price target around $97.68 and implied upside of +30.0% versus the current price.
Average Target
$97.68
7 analysts
Implied Upside
+30.0%
vs. current price
Analyst Count
7
covering this stock
Price Range
$60 - $98
Analyst target range
Analyst coverage for Hinge Health is limited but established, with 7 analysts currently providing estimates. The consensus is implicitly bullish, as evidenced by high growth expectations, including an average revenue estimate of $1.93 billion and an average EPS estimate of $6.66 for the forward period. The wide range between the low EPS estimate of $6.38 and the high of $7.07 indicates some variance in modeling assumptions among analysts. The target price range is not explicitly provided in the data, but the estimated metrics suggest a focus on growth and future profitability. The high EPS estimate of $7.07 likely incorporates assumptions of successful market penetration, sustained high growth rates, and significant operating leverage leading to margin expansion. The low estimate of $6.38 may factor in potential competitive pressures, customer acquisition cost increases, or a slower path to profitability. The absence of a specific consensus price target and the limited number of analysts point to a stock that is still establishing its coverage profile post-IPO, which can contribute to higher volatility and less efficient price discovery.
Bulls vs Bears: HNGE Investment Factors
The evidence presents a classic high-growth, high-risk investment profile. The bull case, anchored in exceptional 51% revenue growth, a premium 80% gross margin, and powerful technical momentum, is currently stronger, driving the stock near its 52-week high. However, the bear case, centered on deep operational losses (-90% net margin) and an extreme valuation premium (PS 6.26x), presents substantial risk. The single most important tension in the investment debate is the timing and magnitude of the company's path to profitability. If HNGE can leverage its high gross margins to rapidly improve operating margins as it scales, the bull thesis will be validated. If profitability remains elusive, the current valuation multiple is unsustainable, and the stock faces significant downside.
Bullish
- Exceptional Revenue Growth: The company is a high-growth disruptor, with recent news citing 51% year-over-year revenue growth. This significantly outpaces the broader market and positions HNGE to capture share in the rapidly digitizing MSK care market.
- Premium Gross Margin Profile: HNGE boasts a robust gross margin of 79.83%, reflecting the high-margin, software-like nature of its digital platform. This provides significant operating leverage potential as the company scales its revenue base.
- Strong Technical Momentum: The stock is in a powerful uptrend, up 74.73% over the past year and 63.42% over the past three months, vastly outperforming the S&P 500. Trading at 98% of its 52-week high ($70.72) signals strong investor conviction and momentum.
- Conservative Balance Sheet: Financial risk is minimized by a very low debt-to-equity ratio of 0.02 and an adequate current ratio of 1.47. This provides a stable foundation to fund its high-growth, loss-making operations without excessive leverage.
Bearish
- Deeply Unprofitable Operations: The company is burning cash, with a net margin of -89.86%, an operating margin of -92.94%, and negative ROE of -139.55%. This underscores the substantial ongoing investment required and raises execution risk on the path to profitability.
- Extreme Valuation Premium: HNGE trades at a rich Price-to-Sales ratio of 6.26x and EV/Sales of 7.95x. This premium valuation leaves the stock vulnerable to multiple compression if growth decelerates or if investor sentiment shifts away from high-growth, unprofitable names.
- Extended Price and High Volatility: Trading at $69.42, near its 52-week high of $70.72, suggests limited near-term upside and high risk of a pullback. A short ratio of 2.24 and a 52-week low of $30.08 (a -57% drawdown) highlight the stock's speculative nature and potential for sharp declines.
- Limited Analyst Coverage and Price Discovery: With only 7 analysts providing estimates and no explicit consensus price target provided, the stock lacks the robust coverage that facilitates efficient price discovery. This can contribute to higher volatility and mispricing risk.
HNGE Technical Analysis
The stock is in a powerful, sustained uptrend, evidenced by a 74.73% gain over the past year, significantly outperforming the broader market's 24.99% return. With a current price of $69.42, the stock is trading near the top of its 52-week range ($30.08 to $70.72), at approximately 98% of that range, indicating strong momentum but also raising concerns about potential overextension and limited near-term upside. Recent momentum has accelerated sharply, with the stock up 26.31% over the past month and 63.42% over the past three months, far exceeding the S&P 500's gains of 0.74% and 15.14%, respectively, which signals a powerful breakout phase diverging from the market's more modest advance. Key technical support is anchored at the 52-week low of $30.08, while immediate resistance is at the 52-week high of $70.72. A decisive breakout above $70.72 would confirm the bullish trend's strength and potentially open the door to further gains, while a failure at this level could trigger a consolidation or pullback. The stock exhibits high volatility, as indicated by a short ratio of 2.24, suggesting elevated speculative interest and the potential for sharp price swings, which necessitates careful risk management for investors.
Beta
—
—
Max Drawdown
-48.5%
Largest decline past year
52-Week Range
$30-$75
Price range past year
Annual Return
+68.7%
Cumulative gain past year
| Period | HNGE Return | S&P 500 |
|---|---|---|
| 1m | +41.8% | -2.2% |
| 3m | +107.3% | +15.8% |
| 6m | +58.1% | +6.4% |
| 1y | +68.7% | +20.9% |
| ytd | +64.9% | +7.7% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
HNGE Fundamental Analysis
Revenue growth is exceptionally strong, with recent news citing a 51% year-over-year increase, positioning Hinge Health as a high-growth disruptor in its sector. While specific quarterly revenue figures are not available in the provided data, the estimated revenue for the forward period is $1.93 billion, indicating the market expects significant scale. The company's gross margin is robust at 79.83%, reflecting the high-margin, software-like nature of its platform business, which is a positive fundamental characteristic. Despite strong top-line growth, the company is currently unprofitable on a net income basis, with a net margin of -89.86% and a trailing EPS of -$0.14. The operating margin is also deeply negative at -92.94%, indicating substantial ongoing investments in sales, marketing, and R&D to fuel growth. The path to profitability is a key focus, with forward-looking metrics like a forward P/E of 20.76x suggesting the market anticipates a significant improvement in earnings in the coming periods. The balance sheet appears conservatively leveraged with a low debt-to-equity ratio of 0.02, minimizing financial risk. Liquidity is adequate with a current ratio of 1.47. However, the negative return on equity (-139.55%) and return on assets (-45.74%) highlight the current stage of heavy investment and lack of profitability. The company's cash flow generation, as implied by a price-to-cash-flow ratio of 21.46, will be critical to monitor as it scales to fund operations internally.
Quarterly Revenue
N/A
N/A
Revenue YoY Growth
N/A
YoY Comparison
Gross Margin
N/A
Latest Quarter
Free Cash Flow
N/A
Last 12 Months
Open an Account, get $2 TSLA now!
Valuation Analysis: Is HNGE Overvalued?
Given the company's negative net income and EPS, the primary valuation metric selected is the Price-to-Sales (PS) ratio. Hinge Health trades at a trailing PS ratio of 6.26x and an Enterprise Value-to-Sales (EV/Sales) of 7.95x. The forward-looking nature of the business is underscored by a forward P/E of 20.76x, which, while not applicable to trailing profits, signals market expectations for rapid earnings generation in the future. The stock's valuation premium is significant when considering industry context, though specific industry average multiples are not provided in the data. A PS ratio of 6.26x and EV/Sales of 7.95x are typically associated with high-growth, high-margin software and platform companies, which aligns with Hinge Health's 79.83% gross margin and disruptive model. This premium is likely justified by investors betting on its superior growth trajectory (51% cited revenue growth) and potential to dominate the digital MSK care market. Historical valuation context is unavailable due to missing historical ratios data. As a company that listed in May 2025, it lacks an extensive public trading history for a meaningful multi-year comparison. Therefore, the current valuation must be assessed primarily against peer companies and its own projected growth path, with the understanding that stocks in their first year of trading can experience heightened valuation volatility.
PE
-8.7x
Latest Quarter
vs. Historical
N/A
5-Year PE Range 17x~59x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
-6.5x
Enterprise Value Multiple
Investment Risk Disclosure
Financial & Operational Risks are severe and center on the company's profound lack of profitability. With a net margin of -89.86% and an operating margin of -92.94%, HNGE is deeply in the investment phase, burning cash to fuel its 51% growth. The negative ROE of -139.55% and ROA of -45.74% confirm that shareholder capital is currently being consumed, not generated. The path to profitability is not just a goal but a necessity for survival, and any stumble in revenue growth or failure to achieve operating leverage would critically undermine the investment thesis. Market & Competitive Risks are elevated due to the stock's premium valuation and nascent public status. Trading at a PS ratio of 6.26x, HNGE is priced for perfection and is highly susceptible to valuation compression if growth expectations are not met or if sector rotation away from high-multiple growth stocks occurs. The stock has demonstrated high volatility, with a short ratio of 2.24 and a 48.52% max drawdown from its recent price history, indicating significant speculative interest and potential for sharp corrections. As a recent IPO, it also faces the risk of lock-up expirations and lacks a long-term track record to instill investor confidence during market downturns. Worst-Case Scenario involves a combination of growth deceleration and a valuation reset. If quarterly revenue growth slows meaningfully from the cited 51% rate, or if the path to profitability is delayed, it could trigger analyst downgrades and a loss of investor confidence. This could lead to a severe derating from its current premium PS multiple towards levels more typical of slower-growth healthcare IT companies. A realistic downside target would be a retest of its 52-week low of $30.08, which represents a -57% decline from the current price of $69.42. Such a move would be consistent with the stock's demonstrated volatility and high-risk profile.
FAQ
The key risks are, in order of severity: 1) Profitability Risk: The company is deeply unprofitable (net margin -89.86%), and failure to achieve operating leverage could lead to continued cash burn and dilution. 2) Valuation Risk: The premium PS ratio of 6.26x makes the stock highly sensitive to any growth disappointment, risking a severe multiple contraction. 3) Execution & Competitive Risk: Sustaining 50%+ growth in a competitive market is challenging, and new entrants or incumbent responses could pressure market share. 4) Volatility Risk: With a short ratio of 2.24 and a 52-week range from $30.08 to $70.72, the stock is prone to extreme price swings.
Our 12-month outlook presents three scenarios. The Base Case (50% probability) sees the stock trading between $60 and $75 as strong growth continues but profitability improves gradually. The Bull Case (25% probability) targets $85 to $100 on sustained hyper-growth and clear profitability progress. The Bear Case (25% probability) warns of a drop to $30 to $45 if growth stalls and losses persist, triggering a valuation reset. The Base Case is most likely, anchored by the analyst forward EPS estimate of $6.66 and the current forward P/E of ~20.76x, implying a price in the low $70s if those earnings are realized.
Based on current financials, HNGE is significantly overvalued, as it trades at a PS ratio of 6.26x while generating a net margin of -89.86%. However, the forward P/E of 20.76x suggests the market is valuing it on anticipated future profits. Compared to typical software or healthcare IT peers, its sales multiple is at a premium, justified by its exceptional 51% growth rate and 80% gross margin. The valuation implies the market expects rapid scaling and a successful transition to strong profitability. Therefore, it is fairly valued only if one shares that optimistic outlook; otherwise, it appears expensive.
HNGE is a compelling but risky investment. For investors with a high risk tolerance and a long-term horizon who believe in its disruptive potential, it could be a good buy on a meaningful pullback. However, at its current price near the 52-week high and with a rich PS ratio of 6.26x, the risk/reward is not attractive for new money. The stock is a 'show me' story where the company must demonstrate a credible path to profitability to justify its valuation. It is not a good buy for conservative or income-seeking investors.
HNGE is unequivocally a long-term investment, unsuitable for short-term trading due to its high volatility and pre-profitability status. The investment thesis is based on capturing multi-year growth as the company scales and eventually achieves profitability, which may take several years. The stock pays no dividend and has a beta likely above 1 (inferred from its market outperformance), indicating higher volatility than the market. Investors should be prepared to hold for a minimum of 3-5 years to allow the business story to fully unfold and to ride out the significant price swings inherent in such a speculative growth stock.